Muscular Dystrophy Canada fund nine new projects through 2023 grant program
NMD4C Investigators involved in many of these exciting clinical and translational research projects
On Thursday March 30th, Muscular Dystrophy Canada (MDC) announced the results of their 2023 Neuromuscular Clinical and Translational Research Grant Program. A dedicated Canadian source of funding for neuromuscular research, this annual funding competition invests in clinical and translational research projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These research grants help fill current gaps in the funding landscape.
This year we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting MDC-funded projects! You can find the full list of funded projects on MDC’s website.
2023 Clinical Research Projects
Establishing the Top Ten Research Priorities for Respiratory Care of Childhood Neuromuscular Disorders ($50,000)
NMD4C investigators and collaborators as project co-investigators and collaborators
Dietary Protein Requirements in Adults with Muscular Dystrophy ($100,000)
Project Lead
Dr Tyler Churchward-Venne
McGill University
NMD4C member as project co-investigator
Dr Mark Tarnopolsky
Muscle MRI in neuromuscular disorders. The era of Artificial Intelligence ($100,000)
NMD4C investigator as project collaborator
B-FIT! Taking exercise away from the hospital into the home environment in people with Oculopharyngeal muscular dystrophy ($100,000)
Project Lead
Dr Eric Voorn
University of Amsterdam
NMD4C investigators and members as project co-investigators and collaborators
Reimagining Rehabilitation for SMA: Patient and Family Perspectives ($83,166)
Project Lead
Dr Jill Glennis Zwicker
University of British Columbia
NMD4C investigators and members as project co-investigators and collaborators
Translational Research Grants
Therapy development for centronuclear myopathy caused by DNM2 gene changes ($100,000)
How genealogies (family histories) can help us understand myotonic dystrophy type 1 ($99,600)
Project Lead
Dr Simon Girard
Université du Québec à Chicoutimi
NMD4C investigators as project co-investigators
Evaluating the impact of stop variants on MLIP’s (Muscular LMNA-Interacting Protein) function in muscle ($100, 000)
Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in models of myotonic dystrophy type 1 ($100 000)
Project Lead
Dr Pascal Chartrand
University of Montreal
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.